Xtandi+Keytruda may still work after ... - Advanced Prostate...

Advanced Prostate Cancer

21,617 members27,074 posts

Xtandi+Keytruda may still work after Xtandi alone fails

Tall_Allen profile image
13 Replies

In a small trial, 5 of 28 men (18%) got a PSA response (dropped at least by half) from the combination even after Xtandi alone failed. Median survival among responders was 42 months (some still alive at follow-up) vs 19 months for non-responders. It is not clear how to choose those who will respond based on tumor biomarkers.

jitc.bmj.com/content/jitc/8...

Written by
Tall_Allen profile image
Tall_Allen
To view profiles and participate in discussions please or .
Read more about...
13 Replies
wpopomaronis profile image
wpopomaronis

Thank you!

MiRob profile image
MiRob

Thanks 😊

Haniff profile image
Haniff

Interesting TA, thanks 😊

Omc64 profile image
Omc64

Hi TA

Could I ask if this means if xtandi fails there are 19 months left...

Also do you know if pembro and xtandi together are being used in Europe in trials or as a treatment?

Thank you for your imput😊

Tall_Allen profile image
Tall_Allen

It only means that in this group of 28 men, many of whom had already had abiraterone, chemo, and other therapies, 14 of the non-responders to the combo therapy lived longer than 19 months. It is not generalizable.

There are these trials of the combination in Europe for mCRPC:

clinicaltrials.gov/ct2/show...

clinicaltrials.gov/ct2/show...

Omc64 profile image
Omc64 in reply to Tall_Allen

Thank you Tall_allen appreciate that info😊

ctarleton profile image
ctarleton in reply to Omc64

Also from the link Tall_Allen originally provided, it might be noted that the trial participants only got 4 rounds of Keytruda, and that due to the relatively small numbers involved there was a considerable 95% Confidence Interval range in the Overall Survival for individuals on either side of that Median value of around 19 months.

"For the 23 non-responders, median follow-up time was 36.5 months;

median PSA PFS time was 3.1 months (95%CI: 2.8 to 4.4 months);

median time to subsequent treatment was 5.2 months (95%CI: 3.8 to 8.5 months);

and overall survival was 18.6 months (95%CI: 13.4 to 26.4 months)."

When it comes to individuals, sometimes "The Median Isn't the Message".

(See also the Classic essay by Stephen J. Gould)

edwardtufte.com/bboard/q-an...

Peterd110 profile image
Peterd110

Thank you!

sotee888 profile image
sotee888

Hi in your opinions would keytruda and xtandi work with someone who has advance bone mets (super scan) and hemo below 8?

Thanks

Tall_Allen profile image
Tall_Allen in reply to sotee888

Super scans with low hemo is a special situation. Is that what your oncologist is suggesting?

sotee888 profile image
sotee888

No I just saw your post and thought it could be an option. My friend has done the Lu 177, chemo, zytiga and now in Xtandi. Dr’s as you would say do not have anything yet they can think off from the tool box. Thanks

Tall_Allen profile image
Tall_Allen in reply to sotee888

I wish I knew more about it, sorry. I would think that Xofigo+Provenge might be useful, but the low red blood cell numbers may preclude that - perhaps discuss with your oncologist.

sotee888 profile image
sotee888 in reply to Tall_Allen

Thanks for your input

Not what you're looking for?

You may also like...

looking for recommendations for top radiation oncologist in Calif or Mayo for second opinions.

My husband had RP in June of 2022 and his PSA started creeping up since September of 2023. His last...

Zanda after Zytiga

Orgovyx and Zytiga brought my Gleason 9 cancer to a PSA of 0.67, but after 5 months my PSA has...

List of drugs by their metastatic prostate cancer cancer fighting properties

I asked ChatGPT to put the following drugs in order of their metastatic prostate cancer cancer...

trelstar

hi warriors. I have been on trelstar for 8 years and was wondering if anyone else has been on it. I...

Prostrate cell division

Does age effect the speed at which prostate cancer cells divide? There are many factors that affect...